PDCD1 polymorphism amplifies the predisposing effect conferred by CTLA4 polymorphism in chronic hepatitis B virus infection

Human Immunology

Volumn 73, Issue 4, 2012, Pages 421-425

  Zhang, Guoyu ^a   Han, Qunying ^a   Duan, Shaoqiong ^a   Li, Zhu ^a   Li, Na ^a   Zhu, Qianqian ^a   Chen, Jinghong ^a   Lv, Yi ^a   Zeng, Xiaoyan ^a   Chen, Yanping ^a   Liu, Zhengwen ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Chronic hepatitis B virus infection; CTLA 4; Interaction; PDCD 1; Polymorphism

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROGRAMMED DEATH 1 LIGAND 1;

ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENE INTERACTION; GENETIC PREDISPOSITION; GENOTYPING TECHNIQUE; HEPATITIS B; HETEROZYGOTE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADULT; ALLELES; CTLA-4 ANTIGEN; EPISTASIS, GENETIC; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGRAMMED CELL DEATH 1 RECEPTOR; YOUNG ADULT;

EID: 84862796732     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2012.01.013     Document Type: Article

References (32)

1. Bertoletti A., Maini M.K., Ferrari C. The host-pathogen interaction during HBV infection: immunological controversies. Antivir Ther 2010, 15(suppl 3):15-24.
2. Maini M.K., Boni C., Lee C.K., Larrubia J.R., Reignat S., Ogg G.S., et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000, 191:1269-1280.
3. + T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009, 10:29-37.
4. Boni C., Fisicaro P., Valdatta C., Amadei B., Di Vincenzo P., Giuberti T., et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007, 81:4215-4225.
5. Evans A., Riva A., Cooksley H., Phillips S., Puranik S., Nathwani A., et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion. Hepatology 2008, 48:759-769.
6. Fisicaro P., Valdatta C., Massari M., Loggi E., Biasini E., Sacchelli L., et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 2010, 138:682-693.
7. Schurich A., Khanna P., Lopes A.R., Han K.J., Peppa D., Micco L., et al. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 2011, 53:1494-1503.
8. Mäurer M., Loserth S., Kolb-Mäurer A., Ponath A., Wiese S., Kruse N., et al. A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics 2002, 54:1-8.
9. Prokunina L., Castillejo-López C., Oberg F., Gunnarsson I., Berg L., Magnusson V., et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002, 32:666-669.
10. Prokunina L., Padyukov L., Bennet A., de Faire U., Wiman B., Prince J., et al. Association of the PD-1.3A allele of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitope. Arthritis Rheum 2004, 50:1770-1773.
11. Probst H.C., McCoy K., Okazaki T., Honjo T., van den Broek M. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol 2005, 6:280-286.
12. Parry R.V., Chemnitz J.M., Frauwirth K.A., Lanfranco A.R., Braunstein I., Kobayashi S.V., et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005, 25:9543-9553.
13. Momin S., Flores S., Angel B.B., Codner D.E., Carrasco P.E., Perez-Bravo F. Interactions between programmed death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) gene polymorphisms in type 1 diabetes. Diabetes Res Clin Pract 2009, 83:289-294.
14. Juran B.D., Atkinson E.J., Schlicht E.M., Fridley B.L., Petersen G.M., Lazaridis K.N. Interacting alleles of the coinhibitory immunoreceptor genes cytotoxic T-lymphocyte antigen 4 and programmed cell-death 1 influence risk and features of primary biliary cirrhosis. Hepatology 2008, 47:563-570.
15. Zhang G., Liu Z., Duan S., Han Q., Li Z., Lv Y., et al. Association of polymorphisms of programmed cell death-1 gene with chronic hepatitis B virus infection. Hum Immunol 2010, 71:1209-1213.
16. Zheng L., Li D., Wang F., Wu H., Li X., Fu J., et al. Association between hepatitis B viral burden in chronic infection and a functional single nucleotide polymorphism of the PDCD1 gene. J Clin Immunol 2010, 30:855-860.
17. Thio C.L., Mosbruger T.L., Kaslow R.A., Karp C.L., Strathdee S.A., Vlahov D., et al. Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection. J Virol 2004, 78:11258-11262.
18. Mohammad Alizadeh A.H., Hajilooi M., Ranjbar M., Fallahian F., Mousavi S.M. Cytotoxic T-lymphocyte antigen 4 gene polymorphisms and susceptibility to chronic hepatitis B. World J Gastroenterol 2006, 12:630-635.
19. Schott E., Witt H., Pascu M., van Boemmel F., Weich V., Bergk A., et al. Association of CTLA4 single nucleotide polymorphisms with viral but not autoimmune liver disease. Eur J Gastroenterol Hepatol 2007, 19:947-951.
20. Duan S., Zhang G., Han Q., Li Z., Liu Z., Chen J., et al. CTLA-4 exon 1 +49 polymorphism alone and in a haplotype with -318 promoter polymorphism may confer susceptibility to chronic HBV infection in Chinese Han patients. Mol Biol Rep 2011, 38:5125-5132.
21. Kouki T., Sawai Y., Gardine C.A., Fisfalen M.E., Alegre M.L., DeGroot L.J. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 2000, 165:6606-6611.
22. Ligers A., Teleshova N., Masterman T., Huang W.X., Hillert J. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun 2001, 2:145-152.
23. Anjos S., Nguyen A., Ounissi-Benkalha H., Tessier M.C., Polychronakos C. A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele. J Biol Chem 2002, 277:46478-46486.
24. Ueda H., Howson J.M., Esposito L., Heward J., Snook H., Chamberlain G., et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003, 423:506-511.
25. Gerold K.D., Zheng P., Rainbow D.B., Zernecke A., Wicker L.S., Kissler S. The soluble ctla-4 splice variant protects from type 1 diabetes and potentiates regulatory T-cell function. Diabetes 2011, 60:1955-1963.
26. Kong E.K., Prokunina-Olsson L., Wong W.H., Lau C.S., Chan T.M., Alarcón-Riquelme M., et al. A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. Arthritis Rheum 2005, 52:1058-1062.
27. Nakamoto N., Cho H., Shaked A., Olthoff K., Valiga M.E., Kaminski M., et al. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog 2009, 5:e1000313.
28. + T lymphocytes in the liver. J Immunol 2007, 178:2714-2720.
29. Peng G., Luo B., Li J., Zhao D., Wu W., Chen F., et al. Hepatitis B e-antigen persistency is associated with the properties of HBV-specific CD8 T cells in CHB patients. J Clin Immunol 2011, 31:195-204.
30. Curran M.A., Montalvo W., Yagita H., Allison J.P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010, 107:4275-4280.
31. Phillips S., Chokshi S., Riva A., Evans A., Williams R., Naoumov N.V. CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J Immunol 2010, 184:287-295.
32. Wang S., Han Q., Zhang G., Zhang N., Li Z., Chen J., et al. CpG oligodeoxynucleotide-adjuvanted fusion peptide derived from HBcAg epitope and HIV-Tat may elicit favorable immune response in PBMCs from patients with chronic HBV infection in the immunotolerant phase. Int Immunopharmacol 2011, 11:406-411.